Phase II trial of irinotecan with biweekly cetuximab in unresectable advanced and/or metastatic colorectal cancer, evaluation of the safety and efficacy based on EGFR positive and KRAS wild type.(i-BEX trial) - Phase II trial of irinotecan with biweekly cetuximab in advanced and/or metastatic colorectal cancer.(i-BEX trial)

PO FMPC (Future Medicine Promoting Consortium)0 个研究点目标入组 45 人开始时间: 2009年11月16日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1)history of severe allergy 2)severe complications paralytic or mechanical bowel obstruction interstitial lung disease pulmonary fibrosis heart failure liver failure renal insufficiency 3)Patients who had received at least cetuximab contained chemotherapy 4)Patients who are impossible to receive irinotecan contained chemotherapy severe infectious disease watery diarrhea massive pleural effusion or ascites Jaundice Patients who is receiving Atazanavir Sulfate 5)Pregnant or lactating women or women of childbearing potential 6)Symptomatic brain metastasis 7)Patients with active double cancer 8)Patients who are considered unfit for enrollment in the study because of mental illness, etc. of clinical relevance 9)Patients with heart disease of clinical relevance 10)Inadequate physical condition, as diagnosed by primary physician

发起方

PO FMPC (Future Medicine Promoting Consortium)